125
Participants
Start Date
June 6, 2022
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
Erie Retina Research, LLC, Erie
Cumberland Valley Retina Consultants, Hagerstown
Marietta Eye Clinic, Marietta
Advanced Research, Coral Springs
Retina Specialists of Tampa, Wesley Chapel
Tennessee Retina, Nashville
Retina Vitreous Associates, Toledo
Foundation for Vision Research, Grand Rapids
Retina Consultants, Fargo
Illinois Retina Associates, S.C., Oak Park
Retinal Vitreal Consultants Ltd., Chicago
Midwest Vision Research Foundation at Pepose Vision Institute, Chesterfield
Retina Consultants of Texas, Bellaire
Retina Consultants of Texas, Katy
Medical Center Opthalmology Associates, San Antonio
Valley Retina Institute, PA, McAllen
Retina Associates of Colorado, Lakewood
California Eye Specialists Medical Group, Pasadena
Macula and Retina Institute, Glendale
Retina Consultants of Orange County, Fullerton
Retinal Consultants Medical Group, Sacramento
Opthalmic Consultants of Boston, Boston
Massachusets Eye Research and Surgery Institution, Waltham
Lead Sponsor
Collaborators (1)
CBCC Global Research
NETWORK
Alimera Sciences
INDUSTRY